BRIVAFUTAL 50 MG ( BRIVARACETAM ) 30 FILM-COATED TABLETS

Brivaracetam is a third-generation antiepileptic drug (AED) and a chemical analog of levetiracetam, specifically designed for higher affinity for the synaptic vesicle protein 2A (SV2A). 

Medical Description and Mechanism

• Classification: It is a racetam derivative and acts as a high-affinity ligand for the SV2A glycoprotein in the brain.
• Mechanism of Action: While the precise mechanism is not fully understood, it is believed to modulate neurotransmitter release (exocytosis) by binding to SV2A, which balances electrical activity in the brain and prevents sudden bursts that cause seizures. It may also have inhibitory effects on sodium channels.
• Pharmacokinetics: It exhibits linear pharmacokinetics, meaning the blood level increases predictably with the dose. It is rapidly and nearly 100% absorbed after oral administration, with minimal (less than 20%) binding to plasma proteins.
• Metabolism: Primarily metabolized in the liver via hydrolysis of its amide group, mediated partly by the CYP2C19 enzyme. 

Therapeutic Indications

• Primary Use: Indicated as adjunctive (add-on) therapy for the treatment of partial-onset seizures (also known as focal seizures).
• Age Range: Approved for use in adults and pediatric patients as young as 1 month of age.
• Formulations: Available as oral tablets, an oral solution (10 mg/mL), and an intravenous (IV) injection. 

Clinical Considerations & Safety

• Controlled Substance: In the United States, it is a Schedule V controlled substance due to its potential for abuse or dependence.
• Psychiatric Warnings: Like other AEDs, it may cause an increased risk of suicidal thoughts or behavior (occurring in approximately 1 in 500 patients).
• Common Side Effects: The most frequent adverse reactions (occurring in >10% of patients) include somnolence (sleepiness), dizziness, and fatigue.
• Withdrawal: Must be tapered gradually; stopping suddenly can trigger status epilepticus (prolonged, life-threatening seizures).
• Drug Interactions: While it has fewer interactions than older AEDs, co-administration with strong CYP inducers like rifampin may require a dose increase of brivaracetam. It may also increase levels of the active metabolite of carbamazepine. 

Write a review